BofA raised the firm’s price target on BridgeBio (BBIO) to $76 from $58 and keeps a Buy rating on the shares. The improvements in muscle damage and ambulatory/ pulmonary functions reported in BBP-418’s positive interim dataset are “compelling,” challenging any bear argument, according to the analyst, who sees reasons to believe the opportunity could surpass the team’s $1B guidance.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $80 from $70 at H.C. Wainwright
- Positive Outlook for BridgeBio Pharma: Buy Rating Affirmed on Strong Phase 3 Trial Results and Strategic Market Positioning
- BridgeBio Pharma Announces Positive Phase 3 Study Results
- BridgeBio Pharma’s Promising Phase 3 Results and Accelerated Approval Path Justify Buy Rating
- BridgeBio price target raised to $69 from $59 at Raymond James